SCHEMBL720543

SCHEMBL720543

COc1ccc2oc(C(Nc3ccc(C(=O)O)cc3)C3CCCCC3)c(C)c2c1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.52
RAB9A P51151 3/20 0.52
POLB P06746 1/20 0.46
TP53 P04637 1/20 0.43
MAPT P10636 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.42
ATM Q13315 1/20 0.40
ALDH1A1 P00352 2/20 0.40
KDM4E B2RXH2 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
KMT2A Q03164 2/20 0.40
RCE1 Q9Y256 1/20 0.40
MAOA P21397 1/20 0.40
MEN1 O00255 1/20 0.40
MAPK1 P28482 1/20 0.40
MITF O75030 1/20 0.40
LMNA P02545 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL721051 0.90 NPC1 (0.45) NPC1RAB9APOLBTP53MAPT
SCHEMBL718278 0.87 NPC1 (0.43) NPC1RAB9APOLBTP53MAPT
SCHEMBL721161 0.87 NPC1 (0.50) NPC1RAB9APOLBTP53L3MBTL1
SCHEMBL721439 0.87 NPC1 (0.51) NPC1RAB9AMAPTATMALDH1A1
SCHEMBL719915 0.86 NPC1 (0.45) NPC1RAB9APOLBTP53MAPT
SCHEMBL14905653 0.85 NPC1 (0.49) NPC1RAB9AMAPTATMALDH1A1
SCHEMBL718372 0.84 RCE1 (0.39) NPC1RAB9AALDH1A1RCE1
SCHEMBL718539 0.83 PIN1 (0.44) NPC1RAB9APOLBMAPTL3MBTL1
SCHEMBL719390 0.82 NPC1 (0.45) NPC1RAB9APOLBTP53MAPT
SCHEMBL716683 0.82 NPC1 (0.43) NPC1RAB9APOLBTP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP NPC1 902/4885RAB9A 2454/4885POLB 4719/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP NPC1 902/4885RAB9A 2454/4885POLB 4719/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.